Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Cingulate Inc. Warrants (CINGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CINGW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -71.43% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 21092 | Beta -0.84 | 52 Weeks Range 0.01 - 0.18 | Updated Date 04/2/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -104.33% | Return on Equity (TTM) -601.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3203367 |
Shares Outstanding - | Shares Floating 3203367 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cingulate Inc. Warrants
Company Overview
History and Background
Cingulate Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD). Cingulate focuses on using flexible-dose and multi-dose delivery technology platform. The company's focus is on improving the lives of patients with ADHD.
Core Business Areas
- Pharmaceutical Development: Researching, developing, and commercializing new medications for ADHD and related disorders.
- Drug Delivery Technology: Focus on flexible-dose and multi-dose technology platform to deliver medication.
Leadership and Structure
Details on leadership structure and key executives are not available publicly for warrants. It would mirror that of Cingulate Inc (CING).
Top Products and Market Share
Key Offerings
- CTX-1301: CTX-1301 is a flexible dose and multi-dose platform being developed by Cingulate for the treatment of ADHD. The competitors for ADHD treatment include companies with existing treatments such as Concerta, Ritalin, Vyvanse (Takeda), and Adderall.
- CTX-1302: CTX-1302 is a flexible dose and multi-dose platform being developed by Cingulate for the treatment of ADHD. The competitors for ADHD treatment include companies with existing treatments such as Concerta, Ritalin, Vyvanse (Takeda), and Adderall.
Market Dynamics
Industry Overview
The pharmaceutical industry for ADHD treatments is competitive and growing, driven by increasing diagnosis rates and the need for improved medications with fewer side effects.
Positioning
Cingulate aims to differentiate itself by developing treatments using a flexible-dose and multi-dose technology platform. Their competitive advantage lies in offering potential improvements over existing medications.
Total Addressable Market (TAM)
The ADHD market is estimated to be in the billions of dollars globally. Cingulate is positioning itself to capture a share of this market through its novel drug delivery technologies.
Upturn SWOT Analysis
Strengths
- Novel Drug Delivery Technology
- Targeted approach to ADHD treatment
- Experienced management team
Weaknesses
- Limited financial resources
- High regulatory hurdles
- Dependence on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other related disorders
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Unfavorable regulatory changes
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TAK
- VRX
- TEVA
Competitive Landscape
Cingulate faces significant competition from established pharmaceutical companies. Its success depends on the differentiation and efficacy of its drug delivery technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is characterized by R&D progress and fundraising efforts.
Future Projections: Future growth projections depend on successful clinical trials and regulatory approvals. Analyst estimates are not readily available for warrants, it would mirror Cingulate Inc (CING).
Recent Initiatives: Recent strategic initiatives include advancing clinical trials for CTX-1301 and CTX-1302.
Summary
Cingulate Inc. is a development-stage company focused on ADHD treatment. The company shows promise with its novel flexible dose technology, but faces significant competition and regulatory hurdles. Clinical trial success is critical for future growth. Financial stability and strategic partnerships are also important considerations for the company's long-term viability.
Similar Companies
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Warrants are derivatives and carry higher risk compared to common stock.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cingulate Inc. Warrants
Exchange NASDAQ | Headquaters Kansas City, KS, United States | ||
IPO Launch date 2021-12-08 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.cingulate.com |
Full time employees 13 | Website https://www.cingulate.com | ||
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.